Ocugen to commercialise India’s Covaxin in CanadaJune 5, 2021
The biopharmaceutical company Ocugen Inc. has joined hands with Bharat Biotech to exclusively co-develop, supply, and commercialise India’s indigenous COVID-19 vaccine Covaxin in Canada, in addition to the United States.
Covaxin has demonstrated excellent safety record in human clinical trials and in vaccine administration under emergency use in India. The vaccine was developed by Bharat Biotech, in collaboration with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV). Covaxin is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform. In addition to generating strong immune response against multiple antigens, Covaxin has been shown to generate memory T cell responses, for its multiple epitopes, indicating longevity and a rapid antibody response to future infections. It is packaged in multi-dose vials that can be stored at 2-8⁰C.
“As we work towards the submission of the emergency use application in the US, we will simultaneously seek authorisation under interim order for emergency use in Canada,” said Dr Shankar Musunuri, Chairman of the Board, Chief Executive Officer, and Co-founder of Ocugen, in a statement.